Lisa Kerr
About
Lisa Kerr is a scholar working on Immunology, Rheumatology and Pathology and Forensic Medicine.
According to data from OpenAlex, Lisa Kerr has authored 25 papers receiving a total of 808 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Immunology, 10 papers in Rheumatology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Lisa Kerr's work include Psoriasis: Treatment and Pathogenesis (16 papers), Rheumatoid Arthritis Research and Therapies (9 papers) and Spondyloarthritis Studies and Treatments (7 papers). Lisa Kerr is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (16 papers), Rheumatoid Arthritis Research and Therapies (9 papers) and Spondyloarthritis Studies and Treatments (7 papers). Lisa Kerr collaborates with scholars based in United States, United Kingdom and Canada. Lisa Kerr's co-authors include Scott J. Jacober, Zvonko Miličević, Peter W.F. Wilson, Itamar Raz, Anselm K. Gitt, Irina Kowalska, György Jermendy, Velimir Božikov, Barbara N. Campaigne and Meng H. Tan and has published in prestigious journals such as Diabetes Care, Clinical Infectious Diseases and Annals of the Rheumatic Diseases.
In The Last Decade
Lisa Kerr
23 papers receiving 768 citations
Peers
Lisa Kerr
Daniele Cappellani Italy
Taner Demirci Türkiye
Arif Yüksel Türkiye
Effie Pournara Switzerland
Dimitrios Boumpas Greece
Junya Ajiro Japan
Zdenko Killinger Slovakia
Selvihan Beysel Türkiye
Christine Azéma France
Citations per year, relative to Lisa Kerr Lisa Kerr (= 1×)
peers
Daniele Cappellani
Countries citing papers authored by Lisa Kerr
Since
Specialization
Citations
This map shows the geographic impact of Lisa Kerr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lisa Kerr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lisa Kerr more than expected).
Fields of papers citing papers by Lisa Kerr
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Lisa Kerr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lisa Kerr. The network helps show where Lisa Kerr may publish in the future.
Co-authorship network of co-authors of Lisa Kerr
This figure shows the co-authorship network connecting the top 25 collaborators of Lisa Kerr. A scholar is included among the top collaborators of Lisa Kerr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lisa Kerr. Lisa Kerr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Coates, Laura C., Sreekumar Pillai, Hasan Tahir, et al.. (2021). Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double‐Blind Withdrawal Study. Arthritis & Rheumatology. 73(9). 1663–1672.
2.
Tsai, Max, Emel Serap Monkul Nery, Lisa Kerr, et al.. (2021). Pharmacokinetics, Safety, and Tolerability of Lasmiditan in Pediatric Patients with Migraine. Clinical Pharmacokinetics. 60(6). 819–828.
3.
Coates, Laura C., Alexis Ogdie, Prashanth Sunkureddi, et al.. (2019). FRI0426 IXEKIZUMAB MAKES REMISSION AND LOW DISEASE ACTIVITY POSSIBLE IN PATIENTS WITH PSORIATIC ARTHRITIS: TWO-YEAR RESULTS IN TNF INADEQUATE RESPONDERS OR BIOLOGIC-NAïVE PATIENTS. Annals of the Rheumatic Diseases. 78. 902–903.
4.
Coates, Laura C., Ana‐Maria Orbai, Akimichi Morita, et al.. (2018). Achieving minimal disease activity in psoriatic arthritis predicts meaningful improvements in patients’ health-related quality of life and productivity. BMC Rheumatology. 2(1). 24–24.
5.
Coates, Laura C., M. Elaine Husni, Éric Lespessailles, Lisa Kerr, & Gaia Gallo. (2018). IXEKIZUMAB MAKES THERAPEUTIC THRESHOLDS POSSIBLE IN ACTIVE PSORIATIC ARTHRITIS PATIENTS: RESULTS FROM SPIRIT TRIALS. 98. 16–17.
6.
Gottlieb, Alice B., Kim Papp, C. Birbara, et al.. (2018). Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis. Journal of the American Academy of Dermatology. 79(3). 593–595.
7.
Reich, Kristian, Kimberley Jackson, Susan Ball, et al.. (2018). Ixekizumab Pharmacokinetics, Anti-Drug Antibodies, and Efficacy through 60 Weeks of Treatment of Moderate to Severe Plaque Psoriasis. Journal of Investigative Dermatology. 138(10). 2168–2173.
8.
Genovese, Mark C., B. Combe, Joel M. Kremer, et al.. (2018). Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2. Lara D. Veeken. 57(11). 2001–2011.
9.
Merola, Joseph F., Phoebe Rich, Jan Dutz, et al.. (2018). THU0313 Ixekizumab improves nail and skin lesions through 52 weeks in patients with active psoriatic arthritis and inadequate response to tumour necrosis factor inhibitors. Annals of the Rheumatic Diseases. 77. 374–375.
10.
Coates, Laura C., Philip J. Mease, Éric Lespessailles, et al.. (2017). FRI0502 Ixekizumab reduces disease activity in active psoriatic arthritis patients who had previous inadequate response to tumour necrosis factor-inhibitors. Annals of the Rheumatic Diseases. 76. 679–679.
11.
Menter, Alan, Richard B. Warren, Richard G. Langley, et al.. (2017). Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER ‐1, UNCOVER ‐2 and UNCOVER ‐3). Journal of the European Academy of Dermatology and Venereology. 31(10). 1686–1692.
12.
Menter, Alan, Kristian Reich, Richard B. Warren, et al.. (2016). 056 Impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER 2. Journal of Investigative Dermatology. 136(9). S170–S170.
13.
Blauvelt, Andrew, Richard G. Langley, Kenneth B. Gordon, et al.. (2016). 388 Ixekizumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in patients with psoriasis. Journal of Investigative Dermatology. 136(9). S227–S227.
14.
Langley, Richard G., Andrew Blauvelt, Ken Gordon, et al.. (2016). Rapidité d’action de l’ixékizumab : analyse groupée de 2 essais randomisés de phase 3 (UNCOVER-2 et 3) chez des patients atteints de psoriasis. Annales de Dermatologie et de Vénéréologie. 143(12). S397–S397.
15.
Malani, Anurag N., et al.. (2014). Alopecia and Nail Changes Associated With Voriconazole Therapy. Clinical Infectious Diseases. 59(3). e61–e65.
16.
Raz, Itamar, Antonio Ceriello, Peter W.F. Wilson, et al.. (2011). Post Hoc Subgroup Analysis of the HEART2D Trial Demonstrates Lower Cardiovascular Risk in Older Patients Targeting Postprandial Versus Fasting/Premeal Glycemia. Diabetes Care. 34(7). 1511–1513.
17.
Siegelaar, Sarah E., Lisa Kerr, Scott J. Jacober, & J. Hans DeVries. (2011). A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction. Diabetes Care. 34(4). 855–857.
18.
Raz, Itamar, Peter W.F. Wilson, Krzysztof Strojek, et al.. (2009). Effects of Prandial Versus Fasting Glycemia on Cardiovascular Outcomes in Type 2 Diabetes: The HEART2D trial. Diabetes Care. 32(3). 381–386.
19.
Ilag, Liza L., Lisa Kerr, James Malone, & Meng H. Tan. (2007). Prandial Premixed Insulin Analogue Regimens Versus Basal Insulin Analogue Regimens in the Management of Type 2 Diabetes: An Evidence-Based Comparison. Clinical Therapeutics. 29(6). 1254–1270.
20.
Frías, Jaime L., H. Eugene Hoyme, Lois Jovanovič, et al.. (2005). Congenital anomaly rate in offspring of mothers with diabetes treated with insulin lispro during pregnancy. Diabetic Medicine. 22(6). 803–807.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Daniele Cappellani Breakdown of academic impact, for papers by Taner Demirci Breakdown of academic impact, for papers by Arif Yüksel Breakdown of academic impact, for papers by Effie Pournara Breakdown of academic impact, for papers by Dimitrios Boumpas Breakdown of academic impact, for papers by Junya Ajiro Breakdown of academic impact, for papers by Zdenko Killinger Breakdown of academic impact, for papers by Selvihan Beysel Breakdown of academic impact, for papers by Christine Azéma